Top Markets
#1 Bedrock Bedrock +50.85%
#2 pippin pippin +21.68%
#3 IQ IQ +20.70%
#4 Naoris Protocol Naoris Protocol +17.39%
#5 Irys Irys +16.18%
#6 Magma Finance Magma Finance +15.58%
#7 ETHGas ETHGas +15.36%
#8 Aria.AI Aria.AI +15.19%
#9 パンチ (Punch) パンチ (Punch) +14.59%
#10 Bitway Bitway +12.30%
Coin of the day
Bedrock Bedrock
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
Fusion Antibodies plc Fusion Antibodies plc

Fusion Antibodies plc

FAB
Clasificación en acciones #20442
Fusion Antibodies plc, a contract research organization, engages in the... Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. It offers monoclonal antibody discovery and development, antibody sequencing, antibody engineering, antibody humanization and rational affinity maturation platform, recombinant protein expression, and stable cell line development and cGMP scale up services. The company serves pharmaceutical, biotech, and diagnostic companies. It has a collaboration partnership with Celonic AG. Fusion Antibodies plc was incorporated in 2000 and is headquartered in Belfast, the United Kingdom.
Precio por acción
$0.16328419
Capitalización bursátil
$204.14K
Cambio (1 día)
4.35%
Cambio (1 año)
102.45%
País
GB
Comercio Fusion Antibodies plc (FAB)

Categoría

Healthcare
Ganancias de Fusion Antibodies plc (FAB)
Ganancias en Sep 2025 TTM: $-2.06M
Secondo gli ultimi rapporti finanziari di Fusion Antibodies plc, gli utili attuali della società sono $-2.06M. Nel 2024, la società ha registrato un utile di $-2.89M, un aumento con respecto a agli utili del 2023, che erano di $-3.53M. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Fusion Antibodies plc desde 2013 hasta 2026
Ganancias al final de cada año
Año Ganancias Cambiar
2026 (TTM) $-2.06M -10.23%
2025 $-2.30M -20.56%
2024 $-2.89M -18.12%
2023 $-3.53M 101.40%
2022 $-1.75M 0.58%
2021 $-1.74M 30.88%
2020 $-1.33M -31.84%
2019 $-1.95M 95.89%
2018 $-997.05K -731.20%
2017 $157.96K 304.33%
2016 $39.07K -126.49%
2015 $-147.46K -26.55%
2014 $-200.78K -72.11%
2013 $-719.78K 0.00%
Ganancias de empresas similares o competidoras
Empresa Ganancias Diferencia de ganancias País
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
$20.46B -992,770.77%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$4.64B -225,408.48%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
$5.23B -253,916.57%
US
UCB SA UCB SA
UCB SA
UCB.BR
$2.14B -103,830.35%
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.45B -70,512.80%
NL